
Ralph K Akyea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9350272/publications.pdf Version: 2024-02-01



Ρλιση Κ Δενέλ

#	Article	IF	CITATIONS
1	Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart, 2019, 105, 975-981.	1.2	86
2	Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care. Lancet Public Health, The, 2019, 4, e256-e264.	4.7	37
3	Sex, Age, and Socioeconomic Differences in Nonfatal Stroke Incidence and Subsequent Major Adverse Outcomes. Stroke, 2021, 52, 396-405.	1.0	28
4	A systematic review showing the lack of diagnostic criteria and tools developed for lowerâ€limb cellulitis. British Journal of Dermatology, 2019, 181, 1156-1165.	1.4	25
5	Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study. Atherosclerosis, 2019, 287, 8-15.	0.4	24
6	Long-term body mass index changes in overweight and obese adults and the risk of heart failure, cardiovascular disease and mortality: a cohort study of over 260,000 adults in the UK. BMC Public Health, 2021, 21, 576.	1.2	23
7	Predicting fracture risk in patients with chronic obstructive pulmonary disease: a UK-based population-based cohort study. BMJ Open, 2019, 9, e024951.	0.8	21
8	Performance and clinical utility of supervised machine-learning approaches in detecting familial hypercholesterolaemia in primary care. Npj Digital Medicine, 2020, 3, 142.	5.7	21
9	Dataâ€driven machineâ€learning analysis of potential embolic sources in embolic stroke of undetermined source. European Journal of Neurology, 2021, 28, 192-201.	1.7	18
10	Obesity and longâ€ŧerm outcomes after incident stroke: a prospective populationâ€based cohort study. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 2111-2121.	2.9	17
11	Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models. BMJ Open, 2020, 10, e034564.	0.8	16
12	Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care. Open Heart, 2021, 8, e001817.	0.9	10
13	Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care. Open Heart, 2021, 8, e001752.	0.9	10
14	Sex disparity in subsequent outcomes in survivors of coronary heart disease. Heart, 2022, 108, 37-45.	1.2	9
15	Case-finding and genetic testing for familial hypercholesterolaemia in primary care. Heart, 2021, 107, 1956-1961.	1.2	9
16	Cost-Effectiveness of Screening Algorithms for Familial Hypercholesterolaemia in Primary Care. Journal of Personalized Medicine, 2022, 12, 330.	1.1	9
17	Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study. BJGP Open, 2020, 4, bjgpopen20X101114.	0.9	8
18	Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis. Pharmacogenomics, 2022, 23, 135-154.	0.6	8

Ralph K Akyea

#	Article	IF	CITATIONS
19	The changing clinical pattern of endemic Burkitt lymphoma in Western Africa: Experience from a tertiary center in Ghana. Pediatric Blood and Cancer, 2018, 65, e27275.	0.8	7
20	Comparison of Risk of Serious Cardiovascular Events after Hemorrhagic versus Ischemic Stroke: A Population-Based Study. Thrombosis and Haemostasis, 2022, 122, 1921-1931.	1.8	6
21	Hip fracture outcomes in patients with chronic obstructive pulmonary disease. British Journal of Anaesthesia, 2018, 121, 1377-1379.	1.5	5
22	Does acupressure help reduce nausea and vomiting in palliative care patients? A double blind randomised controlled trial. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002434.	0.8	5
23	Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. PLoS ONE, 2021, 16, e0260839.	1.1	4
24	LDL cholesterol response to statins and future risk of cardiovascular disease. Heart, 2019, 105, 1290.3-1291.	1.2	3
25	Secondary prevention of cardiovascular disease: Time to rethink stratification of disease severity?. European Journal of Preventive Cardiology, 2019, 26, 1778-1780.	0.8	3
26	Nasal fentanyl alone plus buccal midazolam: an open-label, randomised, controlled feasibility study in the dying. BMJ Supportive and Palliative Care, 2020, 10, 300-303.	0.8	3
27	Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol. BJGP Open, 2021, 5, bjgpopen20X101127.	0.9	3
28	Ethnic disparities in mortality among overweight or obese adults with newly diagnosed type 2 diabetes: a population-based cohort study. Journal of Endocrinological Investigation, 2022, , 1.	1.8	3
29	Understanding social care need through primary care big data: a rapid scoping review. BJGP Open, 2022, 6, BJGPO.2022.0016.	0.9	2
30	Should zinc be used for COVID-19 prophylaxis or treatment? A rapid review. Wellcome Open Research, 0, 5, 188.	0.9	1
31	Behaviours of patients who take their strong opioids as unmeasured â€̃sips'. Journal of Pain and Symptom Management, 2022, , .	0.6	0